A new study suggests that an unidentified cellular source may be responsible for residual viremia in HIV-1 patients on highly active antiretroviral therapy (HAART). This discovery disputes previous theories that attributed residual viremia to latent proviruses in resting CD4+ T cells and could significantly impact eradication efforts.